Basilea Pharmaceu N

Hallo zusammen,

Donnerstag kommen Resultate von Basilea Pharma...

1. Basilea is currently marketing Toctino® (alitretinoin), the only approved treatment for severe chronic hand eczema unresponsive.

2. The company has entered into a global partnership with Astellas Pharma Inc. for its phase III compound isavuconazole, a potential best-in-class azole antifungal, for the treatment of life-threatening invasive fungal infections.

Was ist eure meinung zu dieser firma? lohnenswert? Volumen sind diese woche wirklich niedrig...

3. Full rights to ceftobiprole, the first approved anti-MRSA broad-spectrum cephalosporin antibiotic, for the treatment of potentially life-threatening resistant bacterial infections, will be transferred from Cilag GmbH International, a Johnson & Johnson company, back to Basilea

[/code][/url]

Basilea Pharmaceu N

012 GMT [Dow Jones] Helvea's M&A scenario for Actelion (ATLN.VX) includes a two-step move in which Actelion would first buy Basilea (BSLN.EB) before GlaxoSmithKline (GSK) would take a majority stake in Actelion. The reasoning behind the brokerage's view is that Actelion could make best use of Basilea's tax forwarding losses of about CHF600M and that Basilea would also fit into GlaxoSmithKline's portfolio.



CHF 70 könnte ein gute Support sein Richtung CHF 80.